Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth
PositiveFinancial Markets

- Vivos Therapeutics announced revenue growth in its Q3 2025 earnings call, indicating a positive trajectory for the company despite earnings falling short of expectations by $0.01.
- This revenue growth is significant for Vivos as it demonstrates resilience and potential for future profitability, even as it navigates challenges in meeting earnings targets.
- The broader market context shows mixed performance among companies in the same quarter, with some exceeding expectations while others, like ClearSign and Kingsoft, faced challenges, highlighting varying dynamics in the market.
— via World Pulse Now AI Editorial System





